CA2401070A1 - Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin - Google Patents

Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin Download PDF

Info

Publication number
CA2401070A1
CA2401070A1 CA002401070A CA2401070A CA2401070A1 CA 2401070 A1 CA2401070 A1 CA 2401070A1 CA 002401070 A CA002401070 A CA 002401070A CA 2401070 A CA2401070 A CA 2401070A CA 2401070 A1 CA2401070 A1 CA 2401070A1
Authority
CA
Canada
Prior art keywords
seq
peptide
use according
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002401070A
Other languages
English (en)
Inventor
Martin A. Cheever
Alexander Gaiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of CA2401070A1 publication Critical patent/CA2401070A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

L'invention concerne des compositions et des méthodes destinées au diagnostic et au traitement des cancers associés à l'antigène de la tumeur de Wilms, et en particulier des mésothéliomes. Dans des modes de réalisation particuliers, l'invention concerne de nouvelles méthodes efficaces, des compositions et des kits permettant d'éliciter une réponse immunitaire et une réponse des lymphocytes T aux fragments antigéniques dérivés des polypeptides de l'antigène de la tumeur de Wilms, ainsi que des méthodes d'utilisation de ces compositions dans le diagnostic, la détection, le traitement, le suivi et/ou la prévention du mésothéliome malin de la plèvre chez l'homme.
CA002401070A 2000-02-22 2001-02-22 Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin Abandoned CA2401070A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18407000P 2000-02-22 2000-02-22
US60/184,070 2000-02-22
PCT/US2001/005702 WO2001062920A2 (fr) 2000-02-22 2001-02-22 Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin

Publications (1)

Publication Number Publication Date
CA2401070A1 true CA2401070A1 (fr) 2001-08-30

Family

ID=22675440

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002401070A Abandoned CA2401070A1 (fr) 2000-02-22 2001-02-22 Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin

Country Status (6)

Country Link
EP (1) EP1261711A2 (fr)
JP (1) JP2003524021A (fr)
AU (1) AU2001247220A1 (fr)
CA (1) CA2401070A1 (fr)
NZ (1) NZ521430A (fr)
WO (1) WO2001062920A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US20080070835A1 (en) * 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
EP1708732B2 (fr) 2003-12-01 2016-05-18 Sloan-Kettering Institute For Cancer Research Analogues peptidiques synthetiques de liaison a l'antigene histocompatibilite et leurs utilisations
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US8765687B2 (en) 2005-10-17 2014-07-01 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
CA2645766A1 (fr) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Peptides wt1 immunogenes et leurs methodes d'utilisation
AU2007340679B2 (en) * 2006-12-28 2013-09-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same
PT2119778E (pt) 2007-02-27 2016-02-15 Int Inst Cancer Immunology Inc Método para ativação de célula t auxiliar e composição para utilização no método
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
EP3520810A3 (fr) * 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Peptides wt1 immunogènes et ses utilisations
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
MX369276B (es) 2012-11-13 2019-11-04 Biontech Ag Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
WO2014098012A1 (fr) 2012-12-17 2014-06-26 大塚製薬株式会社 Procédé pour activer des lymphocytes t auxiliaires
US9919037B2 (en) 2013-01-15 2018-03-20 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
MXPA01003344A (es) * 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.

Also Published As

Publication number Publication date
JP2003524021A (ja) 2003-08-12
NZ521430A (en) 2004-04-30
WO2001062920A3 (fr) 2002-07-18
AU2001247220A1 (en) 2001-09-03
EP1261711A2 (fr) 2002-12-04
WO2001062920A2 (fr) 2001-08-30

Similar Documents

Publication Publication Date Title
CA2401070A1 (fr) Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin
JP4130359B2 (ja) Ｗｔ１特異的免疫療法のための組成物および方法
US8071732B2 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
CA2465303C (fr) Compositions et procedes d'immunotherapie specifique a wt1
AU2002367594B2 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20020193329A1 (en) Compositions and methods for the therapy and diagnosis of Her-2/neu-associated malignancies
CZ2003537A3 (cs) Izolovaný polynukleotid
US7323181B2 (en) Compositions and methods for WT1 specific immunotherapy
WO2002013847A2 (fr) Methodes diagnostiques et therapeutiques des tumeurs malignes d'origine hematologiques et virales
CA2383615A1 (fr) Procedes de diagnostic et de therapie de malignites hematologiques ou associees aux virus
WO2001064886A2 (fr) Compositions et procedes pour la detection, le diagnostic et la therapie des malignites hematologiques
US20020150588A1 (en) SPAS-1 cancer antigen
US20030082194A1 (en) Compositions and methods for diagnosis and therapy of malignant mesothelioma
CZ20024213A3 (cs) Prostředky a způsoby léčení a diagnostiky rakoviny prsu
US10316072B2 (en) Immune modulator for immunotherapy and vaccine formulation
US20040175739A1 (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20020058292A1 (en) Ovarian tumor antigen and methods of use therefor
US20020155468A1 (en) Ovarian tumor antigen and methods of use therefor
US7241876B2 (en) Compositions and methods for the therapy and diagnosis of breast cancer
US7704701B2 (en) Diagnosis of prostate cancer with SPAS-1 cancer antigen
US20020064815A1 (en) Ovarian tumor antigen and methods of use therefor
US20030157119A1 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies

Legal Events

Date Code Title Description
FZDE Discontinued